As part of Shape, UCB intends to reduce its workforce by 2000 positions throughout the world, representing approximately 17% of its world-wide workforce.
The company plans to achieve this by making around 2400 positions redundant and by creating around 400 new positions. At the same time, an estimated 300 positions would be re-deployed to UCB’s core sites. This project is subject to the information and consultation procedures which may apply in the different impacted countries.
By this project, UCB aims to increase focus on its core assets, re-deploy its resources, advance R&D and simplify its organization, while successfully delivering the company’s new medicines to patients.
Roch Doliveux, CEO of UCB, said: “We will help our employees to go through the changes ahead of us. Our priority will be to look for solutions that lead to a new future. We aim to achieve this through an open and constructive dialogue with our social partners around the globe.”